08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

AtheroNova Inc financial update

AtheroNova Inc . (OTCBB:AHRO), Irvine, Calif.   Business: Cardiovascular   Date announced: 2015-02-19   Note: AtheroNova is in default on 2.5% senior secured convertible notes, 6% senior secured convertible notes and 8% senior secured convertible...
08:00 , Jan 5, 2015 |  BioCentury  |  Finance

2015 Financial Markets Preview: Show me in 2015

2015 Financial Markets Preview Bankers and buysiders see no reason for the biotech sector to slow down in 2015 as a new innovation cycle continues to churn out products and drive growth in the large-...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Financial News

AthernoNova completes follow-on

AtheroNova Inc. (OTCBB:AHRO), Irvine, Calif.   Business: Cardiovascular   Date completed: 2014-10-28   Type: Follow-on   Raised: $3.1 million   Shares: 4 million   Price: $0.75   Shares after offering: 8.8 million   Underwriters: Aegis...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Financial News

AthernoNova amends follow-on

AtheroNova Inc. (OTCBB:AHROD), Irvine, Calif.   Business: Cardiovascular   Date announced: 2014-09-19   Type: Follow-on   To be raised: Up to $5.8 million   Shares: TBD   Price prior: $0.37   Underwriters: Aegis Capital; Merriman...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

AHRO-001: Phase Ib started

AtheroNova said partner CardioNova, a subsidiary of Maxwell Biotech, expanded a double-blind, placebo-controlled, Russian Phase I trial evaluating AHRO-001 to include a Phase Ib portion that will enroll about 48 patients with hypercholesterolemia. The Phase...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Financial News

AthernoNova financial update

AtheroNova implemented a 1-for-10 reverse stock split and began trading under the ticker "AHROD." Following the split, AtheroNova has 4.3 million shares outstanding. AtheroNova Inc. (OTCBB: AHROD), Irvine, Calif.   Business: Cardiovascular   Date announced:...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

AthernoNova management update

AtheroNova Inc. (OTCBB:AHRO), Irvine, Calif.   Business: Cardiovascular   Hired: Randolph Johnson as COO, formerly chief of technology development and VP of research at KAI Pharmaceuticals Inc. , which Amgen Inc. acquired  ...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Financial News

AthernoNova proposes follow-on

AtheroNova Inc. (OTCBB: AHRO), Irvine, Calif.   Business: Cardiovascular   Date announced: 3/18/14   Type: Follow-on   To be raised: Up to $15 million   Shares: TBD   Price prior: $0.37   Underwriter: Aegis Capital...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

AHRO-001: Completed Phase I enrollment

AtheroNova said its partner OOO CardioNova, a subsidiary of Maxwell Biotech, completed enrollment of about 54 healthy volunteers in a double-blind, placebo-controlled, Russian Phase I trial evaluating daily doses of 18.75-37.5 mg/kg oral AHRO-001. Under...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

AthernoNova, Maxwell Biotech preclinical data

In a mouse model of atherosclerosis, AHRO-001 plus chow for 15 weeks reduced fasting plasma glucose (FPG) levels by 37% vs. chow alone. AHRO-001 plus chow also significantly reduced atherosclerotic lesion size at the aortic...